Correlation of NO metabolites and 8-iso-prostaglandin F2a with periventricular hyperintensity severity

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 24, Issue 9, 2004, Pages 1659-1663

  Shibata, Hiroshi ^a   Nabika, Toru ^a,b   Moriyama, Hidehiko ^a   Masuda, Junichi ^a,b   Kobayashi, Shotai ^a,b  

^a SHIMANE UNIVERSITY   (Japan)

^b Shimane Institute of Health Science   (Japan)

Author keywords

Lacunar infarction; Nitric oxide; Oxidative stress; Small vessel disease; White matter

Indexed keywords

8 ISOPROSTAGLANDIN F2 ALPHA; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; NITRIC OXIDE;

ADULT; AGED; AGING; ARTERIOSCLEROSIS; ARTICLE; BRAIN DISEASE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; MEAN ARTERIAL PRESSURE; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PERIVENTRICULAR HYPERINTENSITY; PRIORITY JOURNAL; RISK FACTOR; WHITE MATTER; WHITE MATTER LESION;

AGE FACTORS; AGED; BRAIN; BRAIN DISEASES; BRAIN INFARCTION; CHOLESTEROL, HDL; DINOPROST; DISEASE PROGRESSION; FEMALE; HUMANS; HYPERTENSION; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NITRIC OXIDE; OXIDATIVE STRESS; RISK FACTORS; TRIGLYCERIDES;

EID: 4444238225     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000137415.67349.3c     Document Type: Article

References (38)

1. Martinez-Lage P, Hachinski V. Multi-infarct dementia. In: Barnett HJM, Mohr JP, Stein BM, Yatsu FM, eds. Stroke: Pathophysiology, Diagnosis, and Management. Philadelphia, Pa: Churchill Livingstone; 1998: 875-894.
2. van Swieten JC, van den Hout JHW, van Ketel BA, Hijdra A, Wokke JHJ, van Gijn J. Periventricular lesions in the white matter on magnetic resonance imaging in the elderly. Brain. 1991;114:761-774.
3. Kobayashi S, Okada K, Yamashita K. Incidence of silent lacunar lesion in normal adults and its relation to cerebral blood flow and risk factors. Stroke. 1991;22:1379-1383.
4. Englund E. Neuropathology of white matter lesions in vascular cognitive impairment. Cerebrovasc Dis. 2002;13(suppl 2):11-15.
5. Carmelli D, DeCarli C, Swan GE, Jack LM, Reed T, Wolf PA, Miller BL. Evidence for genetic variance in white matter hyperintensity volume in normal elderly male twins. Stroke. 1998;29:1177-1181.
6. Schmidt R, Schmidt H, Kapeller P, Lechner A, Fazekas F. Evolution of white matter lesions. Cerebrovasc Dis. 2002;13(suppl 2):16-20.
7. Pantoni L, Garcia JH. Pathogenesis of leukoaraiosis: a review. Stroke. 1997;28:652-659.
8. Griendling KK, Alexander W. Oxidative stress and cardiovascular diseases. Circulation. 1997;96:3264-3265.
9. Dhalla NS, Temsah RM, Netticadan T. Role of oxidative stress in cardiovascular diseases. J Hypertens. 2000;18:655-673.
10. Schmidt R, Hayn M, Fazekas F, Kapeller P, Esterbauer H. Magnetic resonance imaging white matter hyperintensities in clinically normal elderly individuals: correlations with plasma concentrations of naturally occurring antioxidants. Stroke. 1996;27:2043-2047.
11. Traber MG. Measurement of lipid-soluble vitamins-further adjustment needed? Lancet. 2000;355:2013-2014.
12. Schmidt R, Schmidt H, Fazekas F, Kapeller P, Roob G, Lechner A, Kostner GM, Hartung H-P. MRI cerebral white matter lesions and paraoxonase PON1 polymorphisms: three-year follow-up of the Austrian Stroke Prevention Study. Arterioscler Thromb Vasc Biol. 2000;20: 1811-1816.
13. Laplaud PM, Dantoine T, Chapman MJ. Paraoxonase as a risk marker for cardiovascular disease: facts and hypotheses. Clin Chem Lab Med. 1998; 36:431-441.
14. Morrow JD. The isoprostanes: their quantification as an index of oxidant stress status in vivo. Drug Metab Rev. 2000;32:377-385.
15. Patrono C, FitzGerald GA. Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. Arterioscler Thromb Vasc Biol. 1997; 17:2309-2315.
16. Keaney JF, Larson MG, Vasan RS, Wilson PWF, Lipinska I, Corey D, Massaro JM, Sutherland P, Vita JA, Benjamin EJ. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol. 2003;23:434-439.
17. Bloodsworth A. O'Donnell VB, Freeman BA. Nitric oxide regulation of free radical- and enzyme-mediated lipid and lipoprotein oxidation. Arterioscler Thromb Vasc Biol. 2000;20:1707-1715.
18. Kitiyakara C, Wilcox CS. Antioxidants for hypertension. Curr Opin Nephrol Hypertens. 1998;7:531-538.
19. Ota Y, Kugiyama K, Sugiyama S, Ohgushi M, Matsumura T, Doi H, Ogata N, Oka H, Yasue H. Impairment of endothelium-dependent relaxation of rabbit aortas by cigarette smoke extract-role of free radicals and attenuation by captopril. Atherosclerosis. 1997;131:195-202.
20. Nabika T, Nasreen S, Kobayashi S, Masuda J. The genetic effect of the apoprotein AV gene on the serum triglyceride level in Japanese. Atherosclerosis. 2002;165:201-204.
21. Kobayashi S, Okada K, Koide H, Bokura H, Yamaguchi S. Subcortical silent brain infarction as a risk factor for clinical stroke. Stroke. 1997;28: 1932-1939.
22. Notsu Y, Nabika T, Park H-Y, Masuda J, Kobayashi S. Evaluation of genetic risk factors for silent brain infarction. Stroke. 1999;30: 1881-1886.
23. Rhodes PM, Leone AM, Francis PL, Struthers AD, Moncada S. The L-arginine:nitric oxide pathway is the major source of plasma nitrite in fasted humans. Biochem Biophys Res Commun. 1995;209:590-596.
24. Rosselli M, Imthurn B, Keller PJ, Jackson EK, Dubey RK. Circulating nitric oxide (nitrite/nitrate) levels in postmenopausal women substituted with 17β-estradiol and norethisterone acetate: a two-year follow-up study. Hypertension. 1995;25:848-853.
25. Rudic DR, Sessa WC. Nitric oxide in endothelial dysfunction and vascular remodeling: clinical correlates and experimental links. Am J Hum Genet. 1999;64:673-677.
26. Wolfrum S, Jensen KS, Liao JK. Endothelium-dependent effects of statins. Arterioscler Thromb Vasc Biol 2003;23:729-736.
27. 1 receptor blockade. J Am Coll Cardiol. 2003;42: 911-913.
28. Didion SP, Ryan MJ, Didion LA, Fegan PE, Sigmund CD, Faraci FM. Increased Superoxide and vascular dysfunction in CuZnSOD-deficient mice. Circ Res. 2002;91:938-944.
29. Kawashima S, Yamashita T, Miwa Y, Ozaki M, Namiki M, Hirase T, Inoue N, Hirata K, Yokoyama M. HMB-CoA reductase inhibitor has protective effects against stroke events in stroke-prone spontaneously hypertensive rats. Stroke. 2003;34:157-163.
30. 2a. Stroke. 2003;34:776-782.
31. Fazekas F, Kleinert R, Offenbacher H, Schmidt R, Kleinert G, Payer F, Radner H, Lechner H. Pathologic correlates of incidental MRI white matter signal hyperintensities. Neurology. 1993;43:1683-1689.
32. Chimowitz MI, Estes ML, Furlan AJ, Awad IA. Further observations on the pathology of subcortical lesions identified on magnetic resonance imaging. Arch Neurol. 1992;49:747-752.
33. Pantoni L, Garcia JH. Significance of cerebral white matter abnormalities 100 years after Binswanger's report: a review. Stroke. 1995;26: 1293-1301.
34. Bokura H, Kobayashi S, Yamaguchi S, Nagai A, Iijima K, Takahashi K. Silent brain infarction and white matter lesions are risk factors for stroke and cardiovascular accidents: prospective cohort study. Stroke. 2004; 35:316.
35. Schmidt R, Fazekas F, Hayn M, Schmidt H, Kapeller P, Roob, G, Offenbacher H, Schumacher M, Eber B, Weinrauch V, Kostner GM, Esterbauer H. Risk factors for microangiopathy-related cerebral damage in the Austrian stroke prevention study. J Neurol Sci. 1997;152:15-21.
36. Jungersten L, Edlund A, Petersson A-S, Wennmalm A. Plasma nitrate as an index of nitric oxide formation in man: analyses of kinetics and confounding factors. Clin Physiol. 1996;16:369-379.
37. Roberts CK, Vaziri ND, Barnard J. Effect of diet and exercise intervention on blood pressure, insulin, oxidative stress, and nitric oxide availability. Circulation. 2002;106:2530-2532.
38. Tsukada T, Yokoyama K, Arai T, Takemoto F, Hara S, Yamada A, Kawaguchi Y, Hosoya T, Igari J. Evidence of association of the ecNOS gene polymorphism with plasma NO metabolite levels in humans. Biochem Biophys Res Commun. 1998;245:190-193.